HIGHLIGHTS
sEVs from prostate cancer stimulate anchorageindependent growth of recipient cells sEVs from tumor bearing, but not healthy, mice contain b1 integrins sEV stimulation of anchorage-independent growth is dependent on b1 integrins b1 down-regulation in the prostate tumor epithelium impairs EV functions
INTRODUCTION
Prostate cancer (PrCa) is one of the most frequently diagnosed cancers among men and remains a significant clinical challenge (Siegel et al., 2018) . Many factors contribute to disease progression and resistance to therapy, including deregulated interactions between integrins and extracellular matrix (ECM) proteins (Fitzgerald et al., 2008; Wang et al., 2011) . Integrins are a class of heterodimeric transmembrane receptors consisting of a and b subunits that modulate cell adhesion and migration in the tumor microenvironment by binding to specific recognition peptide sequences (Lee et al., 2015; Plow et al., 2000) . They signal through multiple downstream effectors such as Src and focal adhesion kinase (FAK) to modulate important functions of both normal and cancer cells. In particular, b1 integrins are known to contribute to prostate tumor growth (Goel et al., 2010 (Goel et al., , 2013 . Our laboratory has previously shown in TRAMP (transgenic adenocarcinoma of the mouse prostate) mice that b1 integrins contribute to resistance to radiation therapy by inhibiting c-jun NH 2 -terminal kinase (JNK) activity (Goel et al., 2013; Sayeed et al., 2016) . TRAMP mice with a conditional b1 ablation in the prostate have increased survival, decreased primary tumor burden, and decreased metastasis (Goel et al., 2013) .
The b1 integrin subunit heterodimerizes with many different a subunits. In epithelial cells, b1 is often paired with a5 to function as the integrin receptor for fibronectin. The a5 subunit has been linked to cancer development and progression. In particular, there are three different studies implicating the loss of certain microRNAs in different cancers that are responsible for targeting a5 (Cimino et al., 2013; Gong et al., 2016; Yoo et al., 2016) . The a5b1 integrin has been implicated in increasing cancer cell migration, invasion, and resistance to chemotherapy (Li et al., 2013; Miroshnikova et al., 2017; Paul et al., 2015; Zhu et al., 2017) . However, there is less known about the role of the a5b1 integrin in anchorage-independent cell growth.
PrCa cells are capable of transferring proteins, such as integrins, to other PrCa cells via extracellular vesicles (EVs). EVs affect both cancer progression and response to cancer therapy (Minciacchi et al., 2015) . There are multiple subtypes of EVs, including microvesicles (50-2,000 nm), apoptotic bodies (50-5,000 nm) (Junker et al., 2016; Kowal et al., 2016) , and exosomes (exo), which range in size between 30 and 150 nm, and are secreted by the fusion of the multivesicular endosomes with the plasma membrane of the cell (Colombo et al., 2014) . Exo can transfer crucial biological molecules between cells, affecting both normal and pathological processes (Colombo et al., 2014; . Several molecules implicated in PrCa progression are enriched in exo from PrCa cells, including b1 integrins, insulin-like growth factor receptor 1 (IGF-IR), and downstream signaling molecules such as c-Src and FAK (DeRita et al., 2017; Fedele et al., 2015; Krishn et al., 2018, in press; Singh et al., 2016) . In addition, exo-mediated transfer of integrins between PrCa cells functionally affects recipient cancer cells (Fedele et al., 2015; Hamidi et al., 2016; Singh et al., 2016) . PrCa cell exo have also been shown to increase xenograft tumor size when injected intravenously (Hosseini-Beheshti et al., 2016) . Furthermore, large cancer-derived EVs called large oncosomes (1-10 mm) were reported to transfer active AKT1 and increase fibroblast Myc activity after oncosome internalization (Minciacchi et al., 2017) . In addition to pro-tumorigenic molecules, tumor suppressor proteins such as maspin have also been detected in PrCa exo (Dean et al., 2017) . Exo, oncosomes, and other cancer-derived EVs may be a source of biomarkers easily detectable in blood (Minciacchi et al., 2015 (Minciacchi et al., , 2017 and potentially linked to disease outcome and therapy response as observed for circulating tumor cells (You et al., 2016) . Owing to recent updates on EV research (Thery et al., 2018) , this report uses the term small EVs (sEVs) to describe the small (between 50 and 150 nm) EVs previously referred to as exo.
We demonstrate for the first time that tumor-derived b1 integrins are essential for supporting the ability to stimulate anchorage-independent growth of EVs shed by PrCa cells and circulating in the plasma of tumorbearing mice. Although the significance of EVs in disease progression is recognized, there are no studies showing that ''tumor-cell-derived'' EVs are physiologically active. We demonstrate in this study, using EVs from in vitro and in vivo models, that tumor-cell-derived b1 integrins are required for EV-mediated stimulation of anchorage-independent growth. Overall, this study sheds light on the role of EVs and b1 integrins in the progression of PrCa.
RESULTS

b1 Integrins Are Required for Extracellular-Vesicle-Stimulated Anchorage-Independent Growth of Prostate Cancer Cells
Our laboratory has previously demonstrated that integrins are expressed in PrCa-derived EVs (Fedele et al., 2015; Krishn et al., 2018, in press; Lu et al., 2018; Singh et al., 2016) and that b1 integrins promote PrCa cell growth and survival (Goel et al., 2009 (Goel et al., , 2010 Sayeed et al., 2012) . To study b1 integrin function in PrCa EVs, we optimized our purification protocol to improve the purity and reliability of our results. In this study, we utilize small (less than 150 nm) EVs obtained from high-speed differential ultracentrifugation and EVs further purified by flotation in a density gradient. Samples that have been further purified by flotation in a density gradient have been designated small EVs (sEVs). All EVs and sEVs utilized are in the size and density range previously reported (Kowal et al., 2016) . To validate the whole sEV isolation procedure, we analyzed the levels of the sEV markers CD63, CD81, TSG101, and CD9 in each iodixanol gradient fraction from a PC3-derived sEV sample and observed that their levels are the highest in the 1.112 g/mL density fraction (Figures 1A and 1B, upper panels) . The input material is shown in a lighter exposure (Figures 1A and 1B, lower panels) . Calnexin, an ER protein not found in EVs, is not present in these samples, confirming the absence of any contaminants ( Figure 1C) . Our results confirm a previous study using an iodixanol density gradient in which the sEVs are present in the 1.115 g/mL fraction (Kowal et al., 2016) . However, species and biofluid of EV origin can affect the density, as we have found sEVs in the 1.14 g/mL fraction from plasma samples (Krishn et al., 2018, in press ). To functionally analyze sEVs from PrCa cells, we first demonstrated that sEVs isolated from PC3 cells have the expected size range ( Figure 2A ) and are capable of stimulating recipient cell anchorage-independent growth, as compared with vehicle treatment (Figures 2B and 2C) .
Next, to elucidate the role of EV b1 integrins in stimulating anchorage-independent growth of PrCa cells, we conducted in vitro and in vivo experiments. In the in vitro approach, we used PC3 cells with a knockdown of the b1 integrin subunit (designated shb1 PC3 cells; Goel et al., 2010) . As previously reported (Goel et al., 2010) , endogenous levels of b1 integrins in PC3 cells are required for the formation of large colonies in a soft agar matrix ( Figure 3A) . We then isolated EVs from these cells using differential ultracentrifugation. Nanoparticle tracking analysis (NTA) reveals that there are no significant differences in the average particle size upon b1 downregulation ( Figure 3B ). Analysis of colonies R25 mm in diameter, expressed as a percentage of the total number of colonies, shows that the EVs from shb1 PC3 cells lose the ability to stimulate large colony growth compared with their counterparts from mock PC3 cells ( Figures 3C and 3D ). As PC3 cells are a naturally aggressive cell line and have an innate ability to form small colonies in standard media alone, we decided to evaluate larger colonies with size R25 mm in diameter rather than the total colony number. The b1 integrin subunit has many different binding partners in the cell, particularly a5 in epithelial cells, which has been previously associated with the progression of cancer (Cimino et al., 2013; Gong et al., 2016; Yoo et al., 2016) . We therefore analyzed the levels of a5 in PC3 cells and EVs released by these cells upon b1 knockdown. Although the levels of an EV marker, TSG101, are not modified upon b1 integrin downregulation ( Figure 3F ), a5 levels are reduced in those EVs ( Figure 3E ), indicating that the a5 and b1 integrin subunits, as expected, are linked. We additionally examined EV levels of FAK, a downstream effector of the a5b1 integrin, and find that it is also downregulated in EVs upon short hairpin RNA (shRNA) targeting of b1 ( Figure 3F ). Furthermore, we observe that FAK is increased in cells treated with EVs from b1-positive PC3 cells ( Figure 3G ). EVs from shb1 cells do not increase recipient cell FAK levels. Owing to the decreased levels of FAK in shb1 EVs, it is likely that the EVs are transferring FAK to the recipient cells ( Figure 3G ).
We then investigated whether the significant functional differences between EVs from shb1 and mock PC3 cells are due to differences in EV internalization. We treated DU145 PrCa cells with EVs labeled with PKH26 red dye and analyzed internalization by confocal microscopy. We observe that there is no difference in the number of cells that internalized EVs from shb1 and mock PC3 cells ( Figure S1 ). This indicates that EVderived b1 integrins play a functional role as signaling molecules rather than influencing EV internalization. When cells were treated with only PKH26 dye without EVs, there was no evidence of red dye internalization in recipient cells (unpublished data). Together, these results demonstrate the requirement of b1 integrins for the ability of PrCa EVs to stimulate anchorage-independent growth.
Rescue of Functional b1 Integrins Restores the Stimulatory Function of Secreted EVs on Anchorage-Independent Growth
To further demonstrate the importance of b1 integrin expression in PrCa cells for the anchorage-independent function of EVs, we re-transfected shb1 PC3 cells with chicken b1 (Hayashi et al., 1990 ), which would not be targeted by the shRNA against human b1. We first analyzed the total cell lysates (TCL) for chicken b1 expression after transfection and confirm specific expression of chicken b1 in transfected cells ( Figure 4A ). To reach detectable levels of relevant proteins in TCL samples, we loaded nearly three times the amount of protein ( Figure 4A ) as we did when analyzing proteins in EV samples ( Figure 3E ). Flow cytometric analysis of those transfected cells also confirms the expression of chicken b1 on the cell surface ( Figure 4B ). Next, we analyzed the EVs released by those cells. NTA shows that there are no significant differences between the size and abundance of EVs from shb1 PC3 cells transfected with chicken b1 and those transfected with empty vector ( Figure 4C ). We observe that the EV markers CD63, CD81, TSG101, and CD9 are also enriched in the EVs compared with TCL ( Figures 4D and 4E ). The levels of total b1 are increased in EVs from shb1 PC3 cells transfected with chicken b1, along with the downstream signaling protein c-Src ( Figure 4E ).
We then treated PC3 cells with EVs from shb1 PC3 cells transfected with chicken b1 or empty vector and analyzed their anchorage-independent growth. We clearly demonstrate that transfection of shb1 cells with chicken b1 rescues the ability of EVs to stimulate large colony growth of recipient PC3 cells ( Figure 4F ). Once again, colonies R25 mm were counted 2 weeks after seeding in soft agar and expressed as either an absolute number or a percentage of total number of colonies ( Figure 4F , left and right panels). EVs from shb1 PC3 cells transfected with an empty vector caused significantly less colony growth than EVs from the shb1 PC3 cells that were transfected with chicken b1 (Figures 4F and 4G ).
Prostate-Specific Ablation of b1 Integrins in Mice Alters the Protein Content, Physical Properties, and Function of Circulating EVs
The in vitro results prompted us to analyze circulating plasma sEVs from the TRAMP mouse model. After sEV isolation from the plasma of TRAMP mice (n = 6), we demonstrate that the sEV markers CD63 and CD9 are present in the expected sEV density fraction (1.14 g/mL, based on previous study from our laboratory using human plasma; Krishn et al., 2018, in press) ( Figure 5A , right panel)]. We had previously used sucrose density gradient separation to demonstrate enriched levels of b1 integrins and c-Src in sEVs from PrCa cells. Here we confirm that both b1 and c-Src are present predominantly in the same iodixanol density fraction (1.14 g/mL) of TRAMP sEVs as markers CD63 and CD9 (DeRita et al., 2017) ( Figure 5A , right panel). Calnexin is absent from these samples (unpublished data). Conditional ablation of b1 from the prostatic /TRAMP) alters the protein composition and density distribution of sEVs from the blood of these mice (n = 8). The sEV marker CD9 is undetectable in the 1.14 g/mL density fraction. b1 and the downstream signaling protein c-Src, which we have previously shown to be enriched in PrCa EVs (DeRita et al., 2017) , are also absent ( Figure 5A, left panel) . We performed analysis on non-tumorbearing wild-type mice (n = 6) as well and observe that there is no detectable b1, CD63, or CD9 in either the 1.14 g/mL fraction or any of the other nine density gradient fractions ( Figure 5A, middle panel) . In addition, NTA of the 1.14 g/mL fraction shows that the amount of sEVs is approximately two times higher in TRAMP mice versus b1 pcÀ/À /TRAMP mice, whereas the difference between wild-type and TRAMP was less pronounced ( Figure 5B and Table 1 ). However, the tumor masses at the age of 20 weeks are statistically similar between TRAMP and b1 pcÀ/À /TRAMP mice (Table 1) ; this is consistent with our previous findings that b1 plays a role in PrCa progression beyond 20 weeks in TRAMP mice (Goel et al., 2013) . The reduction in the number of sEVs in the 1.14 g/mL fraction between TRAMP and b1 pcÀ/À /TRAMP mice is not due to a reduction in tumor size, but rather due to the fact that b1 integrins in the tumor epithelium may have a role specifically in sEV formation and secretion. Altogether, these data suggest that the b1-positive PrCa tumor epithelial cells are the predominant source of circulating b1 in sEVs and that b1 integrins in the prostatic epithelium contribute to sEV processing into circulation.
Stimulation of Anchorage-Independent Growth by Tumor-Derived Circulating sEVs Is Dependent on b1 Integrins
To see if the effects of cancer-cell-derived EVs are tumor specific and transferrable to an in vivo setting, we next analyzed if there was a difference in function between b1-positive sEVs from TRAMP mice and b1-negative sEVs from wild-type mice. PC3 cells were treated with equal numbers of sEVs from the plasma of either TRAMP or wild-type mice and then analyzed for anchorage-independent growth. It is clear that the b1-positive sEVs from TRAMP mice are able to stimulate anchorage-independent growth, whereas b1-negative sEVs from wild-type (non-tumor-bearing) mice do not ( Figures 6A and 6B ).
Given that the functional studies were performed by treating recipient cells with equal numbers of particles from TRAMP and wild-type sEV samples, we wanted to biochemically examine gradient-purified sEV content in the same manner. Immunoblotting on equal numbers of vesicles was performed ( Figure 6C ). We observe, similar to when the samples were loaded based on volume in Figure 5A , that sEVs from wildtype mice do not exhibit the sEV marker CD63, b1, or c-Src. They also lack a5. This shows that even when examining equal numbers of vesicles, there is a dramatic difference in sEV cargo between wild-type and TRAMP mice. Transmission electron microscopy displays standard size and morphology of sEVs isolated from the wild-type mice ( Figure 6D ) despite not exhibiting the standard protein signature seen in TRAMP mice sEVs ( Figure 6C ) and PrCa cell-line-derived sEVs (Figure 1) .
To validate the function of EV-derived a5b1 observed ex vivo, we first pre-treated EVs from TRAMP mice with ATN-161, an inhibitory peptide to the a5b1 integrin, before incubating them with PC3 cells and assessing their anchorage-independent growth. The concentration of ATN-161 (100 mg/mL) has been previously validated by another group while studying mouse a5b1 function in vitro (Sundaram et al., 2017) . Colonies whose sizes were R25 mm were quantified and expressed as a percent of the total number of colonies. ATN-161 pre-treatment of TRAMP mouse-derived EVs significantly reduces the colony size of EV recipient cells compared with RGE-containing control peptide and vehicle pre-treatment ( Figures 6E and 6F) . These results show that the a5b1 integrin plays a crucial role in EV-mediated stimulation of anchorage-independent growth of PrCa cells. The effects observed with ATN-161 on the EVs is not due to any residual freefloating inhibitor binding directly to the cells because a separate experiment shows that ATN-161 treatment of the cells in the absence of sEVs does not significantly alter their anchorage-independent growth (unpublished data).
As the circulating b1 integrin-containing EVs can originate from a plethora of organs and tissues, we next sought to analyze the role of prostate-derived EV b1 integrins in anchorage-independent growth of cancer cells. We utilized tumor-bearing b1 pcÀ/À /TRAMP mice. After isolating plasma-derived EVs, we evaluated EV abundance and size distribution by NTA. The average EV size from b1 pcÀ/À /TRAMP mice was 121.9 nm and the average EV concentration was 4.7 3 10 10 EVs/mL of plasma ( Figure 6G ). The average size of TRAMP EVs was similar (118.0 nm), whereas the concentration (10.5 3 10 10 EVs/mL of plasma) was twice the amount of b1 pcÀ/À /TRAMP EVs. This is to be expected given our previous results examining gradientpurified sEVs (Table 1) . To determine if prostate-specific b1 is affecting EV function, we analyzed PC3 anchorage-independent growth in response to prostate-derived TRAMP EVs. EVs from b1 pcÀ/À /TRAMP mice do not stimulate anchorage-independent growth of PC3 cells, indicating the importance of b1 expression in the prostate tumor epithelium to the oncogenic ability of secreted EVs ( Figure 6H ).
DISCUSSION
b1 integrins are expressed in many different cell types and contribute to prostate tumor growth. Our study is the first to demonstrate that b1 integrins in EVs, including sEVs, specifically from prostate tumor epithelial cells, or PrCa cultured cells, mediate the stimulatory function of secreted EVs on anchorage-independent growth. Through the use of a genetic mouse model and cell-line-based genetic rescue, we demonstrate that b1 integrins are required for the stimulatory effects of EVs derived from cancer cells on anchorage-independent growth.
b1 integrins may affect the anchorage-independent functions of EVs on recipient cells in multiple ways. b1 integrins are heavily trafficked between the cell surface and endosomal pathway (De Franceschi et al., 2015; Huet-Calderwood et al., 2017) and are known to signal through endosomes ; thus they are likely to influence the biology of secreted EVs. Another possible role for b1 in EV functions is that they may influence the composition of EVs secreted from cancer cells as shown in a previous study from our laboratory on other integrins (Lu et al., 2018) . Finally, as it is known that a single cell type can produce many different subsets of EVs, it is possible that b1 integrins are contributing to the biogenesis of, and are carried in, a specific subset of EVs that exhibit tumorigenic effects on recipient cells. Our results indicate that b1 may be playing its role in stimulating anchorage-independent growth at the cell surface, but does not affect the ability of EVs to be internalized by recipient cells.
We have established a requirement for b1 in circulating EVs to stimulate in vitro anchorage-independent growth, which suggests that these EVs are able to potentially modulate both primary and metastatic tumor growth. Furthermore, there is evidence of integrins from cancer-derived EVs altering the function of other non-epithelial, non-cancerous cell types. For example, exo from myeloid leukemia cells have been shown to stimulate angiogenic behavior of recipient endothelial cells (Mineo et al., 2012) . Another study has shown that pancreatic cancer-derived exo contribute to pre-metastatic niche formation in the liver (Costa-Silva et al., 2015) . Furthermore, we have previously demonstrated the transfer of b6-positive EVs to monocytes, causing their M2 polarization (Lu et al., 2018) .
b1 integrin-mediated signaling occurs through a complex network of proteins, including JNK, Src, IGF-IR (Goel et al., 2013; Sayeed et al., 2013 Sayeed et al., , 2016 Varkaris et al., 2014) , and FAK, a non-receptor tyrosine kinase that, with Src, coordinates cell adhesion and cytoskeletal dynamics and regulates cancer cell migration and invasion (Varkaris et al., 2014) . Our previous studies have shown that FAK, Src, and IGF-IR are detected in PrCa EVs and thus may be involved in EV-mediated tumorigenic cell growth. We have previously demonstrated a functional interdependence between the a5b1 integrin and IGF-IR in PrCa cells and that this interaction influences androgen receptor activity and cancer cell growth (Sayeed et al., 2012) . IGF-IR specifically stabilizes the a5b1 integrin by preventing proteasomal degradation but has no effect on the a2, a4, a6, and a7 subunits function and integrin-IGF-IR cross talk in cancer cell growth (Sayeed et al., 2012 (Sayeed et al., , 2016 , and IGF-IR enrichment in PrCa EVs (DeRita et al., 2017) , IGF-IR may support a5b1 stability and promote EV functions. FAK is also associated with b1 signaling and cancer cell survival in the absence of ECM attachment . As we see that EV FAK levels correlate with b1 and that recipient cells have increased FAK upon transfer of b1 and FAK-positive EVs, it is possible that FAK is also a driver of EVmediated stimulation of cancer cell anchorage-independent growth.
Our findings implicate that b1 integrins in the prostate tumor epithelium may be involved in the formation and secretion of EVs. This was evidenced by the fact that the total number of circulating EVs was twice as high in the TRAMP mice compared with the b1 pcÀ/À /TRAMP mice, which at 20 weeks show comparable tumor sizes (Table 1) . We have also demonstrated that the prostate tumor epithelial cells are responsible for nearly all the circulating b1-positive EVs that express canonical markers such as CD9 and CD63. Overall, this study demonstrates that circulating EV b1 integrins shed by prostate tumors are activators of cancer cell growth, thus opening new perspectives in translational medicine and cancer treatment. 
Limitations of the Study
This study performed using a mouse model needs to be translated in human subjects. Furthermore, at this time, although the results may be informative for early-stage cancer diagnosis, they may not provide insightful information on advanced disease.
METHODS
All methods can be found in the accompanying Transparent Methods supplemental file. 
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Statistical Analysis
Unless otherwise indicated, data in the figures are presented as mean ± SEM, and significant differences between experimental groups were determined using the 2-tailed Student's t test. A two-sided P value of less than 0.05 was considered statistically significant. or mock PC3 cells for 24 hours and confocal microscopy was carried out to evaluate EV internalization. DAPI was used to detect nuclei (blue), FITC-labelled Phalloidin was used to label actin (green), and PKH26 Red was used to label the EVs (red). Z-stack analysis was used to determine the presence of EVs inside the cells versus the cell surface. (B) The percent of total cells showing internalized EVs was quantified and reported.
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